A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
about
Progress in systemic therapy of advanced hepatocellular carcinomaDiagnostic and Therapeutic Approaches to Hepatocellular Carcinoma: Understanding the Barcelona Clínic Liver Cancer ProtocolResponse biomarkers: re-envisioning the approach to tailoring drug therapy for cancerComparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunctionClinical trials in hepatocellular carcinoma: an update.A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy.Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy.Extrahepatic metastasis of hepatocellular carcinoma arising from a hepatic adenoma without concurrent intrahepatic recurrence.Molecular classification of hepatocellular carcinoma: potential therapeutic implications.Bioengineered three-dimensional co-culture of cancer cells and endothelial cells: A model system for dual analysis of tumor growth and angiogenesis.CT spectral imaging for monitoring the therapeutic efficacy of VEGF receptor kinase inhibitor AG-013736 in rabbit VX2 liver tumours.Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models.Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight.Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis
P2860
Q26740217-7FF0D8E2-0C6A-494E-9B35-B1F5251C16D1Q28071608-6B117E0E-1E2E-44C5-A27A-3D2D0598A855Q28074295-A25DAC00-709B-4803-AB5D-5A1251D9A27CQ35419331-FBA32602-377F-408C-9838-65ABA9558DE9Q37435638-F276F548-B75E-47A0-B7F5-6B848755A192Q38375159-2ADD7605-E9AF-4116-8C16-3E50333B1B66Q38635603-C3B9A6EA-9575-4F76-A481-4A3FC53030BDQ39143305-63DDCB16-FA60-4477-BD93-4F772B01755DQ39366121-AB4BC40E-F6BD-4D2F-9AAB-4FC02052C023Q41344288-03704AE2-9C69-49E4-92B1-3B2DF6A04183Q41547474-64E789B7-079D-4882-8D24-7A976ED209A7Q41559563-F2C32AB2-114F-488A-A715-5F0B125AFD44Q43059019-841FF597-C0E0-493F-B8F2-76943F85ED53Q48043061-E0FED56C-63A2-45A1-A853-3E240CE32471Q51709008-2D5EC1B6-150C-4A29-A1C2-511C14C8ADD6Q52337612-170F56D9-50DD-4D5F-982E-7F768BBABA1CQ52345488-62E9E93C-C170-4113-B4F7-33178F710863Q57825996-0CD0CB80-F5FE-465C-8DF5-A7EB813D65C7
P2860
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A phase II trial of second-lin ...... nced hepatocellular carcinoma.
@ast
A phase II trial of second-lin ...... nced hepatocellular carcinoma.
@en
type
label
A phase II trial of second-lin ...... nced hepatocellular carcinoma.
@ast
A phase II trial of second-lin ...... nced hepatocellular carcinoma.
@en
prefLabel
A phase II trial of second-lin ...... nced hepatocellular carcinoma.
@ast
A phase II trial of second-lin ...... nced hepatocellular carcinoma.
@en
P2093
P2860
P50
P356
P1433
P1476
A phase II trial of second-lin ...... anced hepatocellular carcinoma
@en
P2093
Anne M Horgan
Jennifer J Knox
Kelly W Burak
Mehrdad Sinaei
Oliver F Bathe
Patrik Rogalla
P2860
P304
P356
10.1002/CNCR.29227
P407
P577
2015-01-06T00:00:00Z